Product logins

Find logins to all Clarivate products below.


Stacey Chang-Douglass

Head of Health Economics and Director in Consulting

Stacey is Head of Health Economics and Director in Consulting at Clarivate.

Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.

Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.

Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.

Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.

Related resources

生物制药领域中隐藏于公开信息中的竞争信号 生物制药领域中隐藏于公开信息中的竞争信号
Blog June 24, 2026
生物制药领域中隐藏于公开信息中的竞争信号
在生命科学领域部署代理式 AI 的五大经验教训 在生命科学领域部署代理式 AI 的五大经验教训
Blog June 16, 2026
在生命科学领域部署代理式 AI 的五大经验教训
AI/机器学习
支付方愿意为便利性买单的市场准入“最佳切入点” 支付方愿意为便利性买单的市场准入“最佳切入点”
Blog June 3, 2026
支付方愿意为便利性买单的市场准入“最佳切入点”
医疗保险 定价 市场准入 真实世界数据 美国市场 药政法规
一种药物,七个名称:药物竞争情报数据背后隐藏的复杂性 一种药物,七个名称:药物竞争情报数据背后隐藏的复杂性
Blog June 2, 2026
一种药物,七个名称:药物竞争情报数据背后隐藏的复杂性
市场准入 案例研究 药政法规